Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

The in Vivo Contributions of TASK-1-Containing Channels to the Actions of Inhalation Anesthetics, the α2 Adrenergic Sedative Dexmedetomidine, and Cannabinoid Agonists

Anni-Maija Linden, M. Isabel Aller, Elli Leppä, Olga Vekovischeva, Teemu Aitta-aho, Emma L. Veale, Alistair Mathie, Per Rosenberg, William Wisden and Esa R. Korpi
Journal of Pharmacology and Experimental Therapeutics May 2006, 317 (2) 615-626; DOI: https://doi.org/10.1124/jpet.105.098525
Anni-Maija Linden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Isabel Aller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elli Leppä
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Vekovischeva
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teemu Aitta-aho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma L. Veale
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alistair Mathie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Rosenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Wisden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esa R. Korpi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Inhalation anesthetics activate and cannabinoid agonists inhibit TWIK-related acid-sensitive K+ channels (TASK)-1 two-pore domain leak K+ channels in vitro. Many neuromodulators, such as noradrenaline, might also manifest some of their actions by modifying TASK channel activity. Here, we have characterized the basal behavioral phenotype of TASK-1 knockout mice and tested their sensitivity to the inhalation anesthetics halothane and isoflurane, the α2 adrenoreceptor agonist dexmedetomidine, and the cannabinoid agonist WIN55212-2 mesylate [R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3,-de]-1,4-benzoxazinyl]-(1-naphtalenyl)methanone mesylate)]. TASK-1 knockout mice had a largely normal behavioral phenotype. Male, but not female, knockout mice displayed an enhanced acoustic startle response. The knockout mice showed increased sensitivity to thermal nociception in a hot-plate test but not in a tail-flick test. The analgesic, sedative, and hypothermic effects of WIN55212-2 (2–6 mg/kg s.c.) were reduced in TASK-1 knockout mice. These results implicate TASK-1-containing channels in supraspinal pain pathways, in particular those modulated by endogenous cannabinoids. TASK-1 knockout mice were less sensitive to the anesthetic effects of halothane and isoflurane than wild-type littermates, requiring higher anesthetic concentrations to induce immobility as reflected by loss of the tail-withdrawal reflex. Our results support the idea that the activation of multiple background K+ channels is crucial for the high potency of inhalation anesthetics. Furthermore, TASK-1 knockout mice were less sensitive to the sedative effects of dexmedetomidine (0.03 mg/kg s.c.), suggesting a role for the TASK-1 channels in the modulation of function of the adrenergic locus coeruleus nuclei and/or other neuronal systems.

Footnotes

  • This work was supported by the German Research Council (Grant DFG WI 1951/1-2) (to W.W.), by Volkswagen Stiftung (Grant I/78 554) (to W.W.), by the Academy of Finland (to E.R.K.), and by the Sigrid Juselius Foundation (to E.R.K.).

  • doi:10.1124/jpet.105.098525.

  • ABBREVIATIONS: TASK, TWIK-related acid-sensitive K+ channel; TWIK, tandem P domain weak inwardly rectifying K+ channels; K2P, two-pore-domain background K+; WIN55212-2 mesylate, R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3,-de]-1,4-benzoxazinyl]-(1-naphtalenyl)methanone mesylate); PPI, prepulse inhibition; LORR, loss of righting reflex; LOTW, loss of tail withdrawal reflex; GTPγ[35S], guanosine-5′-O-(3-[35S]thio)-triphosphate; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; ANOVA, analysis of variance; MAC, minimum alveolar concentration; TREK, TWIK-related K+ channel.

  • ↵1 Current affiliation: Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, Scotland.

    • Received November 10, 2005.
    • Accepted January 4, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue 3
1 Jun 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The in Vivo Contributions of TASK-1-Containing Channels to the Actions of Inhalation Anesthetics, the α2 Adrenergic Sedative Dexmedetomidine, and Cannabinoid Agonists
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

The in Vivo Contributions of TASK-1-Containing Channels to the Actions of Inhalation Anesthetics, the α2 Adrenergic Sedative Dexmedetomidine, and Cannabinoid Agonists

Anni-Maija Linden, M. Isabel Aller, Elli Leppä, Olga Vekovischeva, Teemu Aitta-aho, Emma L. Veale, Alistair Mathie, Per Rosenberg, William Wisden and Esa R. Korpi
Journal of Pharmacology and Experimental Therapeutics May 1, 2006, 317 (2) 615-626; DOI: https://doi.org/10.1124/jpet.105.098525

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

The in Vivo Contributions of TASK-1-Containing Channels to the Actions of Inhalation Anesthetics, the α2 Adrenergic Sedative Dexmedetomidine, and Cannabinoid Agonists

Anni-Maija Linden, M. Isabel Aller, Elli Leppä, Olga Vekovischeva, Teemu Aitta-aho, Emma L. Veale, Alistair Mathie, Per Rosenberg, William Wisden and Esa R. Korpi
Journal of Pharmacology and Experimental Therapeutics May 1, 2006, 317 (2) 615-626; DOI: https://doi.org/10.1124/jpet.105.098525
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • VTA Muscarinic M5 Receptors and Effort-Choice Behavior
  • Substituted Tryptamine Activity at 5-HT Receptors and SERT
  • KRM-II-81 Analogs
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics